Efficacy and safety of recombinant human prourokinase by catheter thrombolysis in the treatment of acute lower extremity deep venous thrombosis
Objective To study the efficacy and safety of recombinant human prourokinase(rhPro-UK)in the treatment of acute lower extremity deep venous thrombosis(DVT)by catheter thrombolysis,in order to provide reference for the treatment of patients with acute DVT.Methods A total of 160 patients with acute DVT admitted from January 2021 to December 2022 were selected as the research objects.According to the computer random numbering method,the patients were divided into reference group and experimental group,with 80 cases in each group.Both groups received basic treatment and implantation of inferior vena cava filter.On this basis,the reference group received intravenous infusion of urokinase thrombolytic therapy,and the experimental group received rhPro-UK by catheter thrombolysis therapy.The clinical efficacy,incidence of adverse events,leg circumference of affected limbs and incidence of post thrombotic syndrome(PTS)were compared between the two groups.Results The total effective rate of treatment in the experimental group was 86.25％,which was higher than 50.00％in the reference group,and the difference was statistically significant(P＜0.05).There were no significant difference in the incidences of pulmonary embolism,bleeding and nausea and vomiting between the two groups during hospitalization(P＞0.05).After treatment,the thigh and calf circumference of the affected limbs in the two groups were smaller than those before treatment,and those in the experimental group were smaller than the reference group,and the differences were statistically significant(P＜0.05).The total incidence of PTS in the experimental group was 17.50％,which was lower than 32.50％in the reference group,and the difference was statistically significant(P＜0.05).Conclusion The rhPro-UK by catheter thrombolysis in the treatment of acute DVT patients has better efficacy and safety,and it can improve the swelling of the affected limb and reduce the risk of PTS.
lower extremity deep venous thrombosisrecombinant human prourokinasecatheter thrombolysis
NETL
NSTL
万方数据
